

Harold S. Geneen Charitable Trust
Awards Program
for Coronary Heart Disease Research

2027 Grant Cycle Office Hours

May 28, 2026



Who We Are

Britta Magnuson, DMD (she/her)

Senior Scientific Advisor

Biomedical Research Grantmaking

Morenike Akinwolere, MSW (she/her)

Grants Associate

Biomedical Research Grantmaking

**HEALTH
RESOURCES
IN ACTION**



Health Resources in Action partners with individuals, organizations, and communities to transform the practices, policies, and systems that improve health and advance equity.



Office Hours Agenda



- Program Goals
- Research Focus and Stage
- Program Overview
- Eligibility
- Review Criteria
- Features of Successful Projects
- Pitfalls to Avoid
- Application Tips
- Q & A

The Geneen Program was created to establish:

“...a more direct and personalized relationship with grant recipients than is normally possible in dealing with the diffuse and bureaucratic administrations through which large organizations are managed...and to support smaller institutions rather than major universities or medical complexes which have a demonstrated capacity to raise funds from the public generally.”



Program Goals

Supports research in the prevention of coronary heart disease or circulatory failure and improving care for patients with these medical conditions.

Research Focus and Stage

- Basic and translational scientific research.
- *Clinical studies are currently ineligible.**

*Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. [Glossary | grants.nih.gov](#)



Basic Research

- Defining mechanisms, targets, and lead molecules related to prevention of coronary heart disease or circulatory failure and improving care

Translational Research (T0)

- New methods of diagnosis, treatment, and prevention of coronary heart disease or circulatory failure and improving care

[What is Translational Research? | UAMS Translational Research Institute](#)

Program Overview

Award Duration: 24 months

**Maximum Award Amount:
(including 10% indirect costs)** Up to \$250,000

Portal Open for
Submissions

May 13, 2026

July 7, 2026

Application
Deadline

Award
Notifications

Mid
November

Award Start
Date

January 1,
2027

Award End
Date

December 31,
2028

Eligibility

Invited institutions may
nominate 1 project each cycle

List available here:

hria.org/grants/Geneen/



- Full-time faculty member.
- United States citizenship is not required.
- To encourage the support of junior faculty, applicants are **ineligible** if at the time of application, they have **combined federal and non-federal funding totaling \$500,000 or more in direct costs** during the first year of the Geneen Award.*

**This figure refers to external funding only and not an applicant's start-up package, other intramural support, or the Geneen Award itself. Applicants may hold a K Award or be in the R00 phase of a K99/R00 as long as those award amounts, combined with other funding, do not exceed these specified limits.*

Review Criteria

- The proposed research has the potential to improve the prevention and treatment of coronary heart disease or circulatory failure (understanding, prevention/treatment).
- Hypothesis and Research Aims are clearly stated, based on sound precedents, and supported by relevant literature and preliminary data (if applicable).
- The applicant is qualified and supports the conduct of an innovative and successful research project. The research award would positively impact the development of the applicant's cardiovascular research program
- Research methodology, data collection, and data analyses are appropriate, thorough, well-specified and appropriate to the proposal's aims.
- The research project is of high quality and originality.
- The timeline and budget align with a scope of work that can be completed within a two-year timeframe.
- Objectives that are well thought out, realistic, and technically feasible.

Common Features of Successful Projects

- **Focus:** The proposed research clearly outlines the potential it has to improve the prevention and treatment of coronary heart disease or circulatory failure (the understanding and/or prevention/treatment).
- **Project:** Sound precedents, preliminary data, and clear rationale; feasible and sufficiently powered; alternative approaches outlined.
- **Grantsmanship:** Clear language and hypothesis understandable to a general audience and appropriate use of jargon and abbreviations.
- **Feasibility:** The project budget and timeline/milestones clearly outline how the project will be completed in the 2-year timeframe.

Common Pitfalls

- Lacking in preliminary data or alternative approaches.
- Poor grantsmanship, proposals are too dense and include too much jargon and are not understandable to a general audience.
- Lack of clarity in regard to the novelty of the project.
- Feasibility unclear.
- Lacking the correct expertise to conduct the study.

Application Tips

- Be realistic (in timeline, budgets, etc.)
- Avoid jargon and abbreviations; should be understandable to scientific generalists
- Be concise and clear (make it easy to read!)
- Include contingencies
- Seek feedback (internally, externally, and across disciplines)

Example Reviewer Feedback - Strengths

- “The hypothesis and research aims are well supported by precedent and the preliminary data.”
- “Comprehensive methods for the assessment...”
- “Highly novel line of investigation.”
- “Well thought out in vitro experiments have been proposed that will provide a comprehensive assessment...”
- “Overall, well written and logical proposal. Has nice and helpful schematics showing the workflow and hypothesis. Preliminary data are ample. This work will potentially fuel years of research downstream.”

Example Reviewer Feedback - Concerns

- “Overwhelming and densely written proposal. This proposal will benefit from the schematic illustration showing a workflow and hypothesis. Preliminary data are ample, but it is unclear how much is done already.”
- “No preliminary data or pilot studies in Aim 2...have been provided making it difficult to assess feasibility.”
- “Specific mechanistic experiments would help address these limitations.”
- “Therefore, there are major concerns that the experimental model will not be suitable for the proposed studies – this could be addressed by more robust references or preliminary studies.”

Questions?

Contact Us:

GeneenAwards@hria.org

**Guidelines, Terms, and
Forms:**

hria.org/grants/Geneen/

